Tricida Inc (TCDA) USD0.001
$2.57
(7.45%)
- Add to watchlist
- This stock can be held in a
$2.57
(7.45%)
$2.57
(7.45%)
Business summary
Tricida, Inc. is a late-stage pharmaceutical company focused on the discovery and clinical development of non-absorbed therapeutics to address renal, metabolic and cardiovascular disease. The Company's lead program, TRC101 is a treatment for chronic kidney disease (CKD). The Company is engaged in developing a non-absorbed drug to enable safety and efficacy for chronic treatment of CKD patients. The TRC101 drug acts in the gastrointestinal tract and clears the human body through the digestive system, by preventing degradation and systemic uptake.
Contact details
Important dates
General stock information
- Short code:
- TCDA
- ISIN:
- US89610F1012
- Market cap:
- $1.69 billion
- Shares in issue:
- 49.14 million
- Sector:
- Pharmaceuticals
- Exchange:
- NASDAQ
- Country:
- United States
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.